Jacob Marcus

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

25h-index5.3kcitations60works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(14), Alzheimer's disease research and treatments(14), Sleep and Wakefulness Research(12), Lysosomal Storage Disorders Research(11), Regulation of Appetite and Obesity(9)

Publications60 total

The Novel PET Radioligand [ <sup>11</sup> C]MK‐7337 Detects Alpha‐Synuclein Pathology in Parkinson's Disease Patients
Alzheimer s & Dementia·2025Open Access
Glucosylsphingosine is a potential fluid-based biomarker of lysosomal dysfunction in Cln3Δex7/8 mice
Neurobiology of Disease·2025· 1 citedOpen Access
Promoting Secretion of Pathological Tau Species Using an Induced Proximity Platform That Engages the Autophagy Pathway
ACS Chemical Neuroscience·2025
Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease
ACS Chemical Biology·2024· 1 cited
P06-22 Prevalidation of Epi2SensA, an assay using gene expression with the EpiDerm RHE model to predict skin sensitization in vitro
Toxicology Letters·2024· 1 cited
AnNoBrainer, An Automated Annotation of Mouse Brain Images using Deep Learning
Neuroinformatics·2024Open Access
AnNoBrainer, an Automated Annotation of Mouse Brain Images using Deep Learning
2024Open Access
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections
ACS Medicinal Chemistry Letters·2023· 1 citedOpen Access
Discovery of Novel Ophthalmic Imaging Biomarkers for Neurodegenerative Disease
Alzheimer s & Dementia·2023Open Access
Progress in imaging by α‐synuclein Positron Emission Tomography
Alzheimer s & Dementia·2023Open Access
A proteogenomic view of Parkinson’s disease causality and heterogeneity
npj Parkinson s Disease·2023· 51 citedOpen Access
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson’s Disease
ACS Medicinal Chemistry Letters·2023· 11 citedOpen Access
Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions
Journal of Neuroscience·2022· 35 citedOpen Access
Parkinson’s disease causality and heterogeneity: a proteogenomic view
2022· 1 citedOpen Access
Validation of a multiplexed and targeted lipidomics assay for accurate quantification of lipidomes
Journal of Lipid Research·2022· 18 citedOpen Access
The <i>GBA1</i> D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
Disease Models & Mechanisms·2022· 16 citedOpen Access
Neuronopathic GBA1 L444P mutation accelerates Glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
2022· 2 citedOpen Access
Parkinson’s disease causality and heterogeneity: a proteogenomic view
2022· 3 citedOpen Access
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
Neurobiology of Disease·2021· 20 citedOpen Access
Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction
Neurobiology of Aging·2021· 17 cited
page 1 of 3Next →

Frequent Co-authors

Sean M. Smith(18), Joel K. Elmquist(11), Robert E. Drolet(7), Mali Cosden(7), Joel B. Schachter(6), Michelle Pearson(6), Sarah Jinn(6), Jason M. Uslaner(6), Nathan G. Hatcher(6), Charlotte E. Lee(5), Clifford B. Saper(5), Xiaohai Wang(5), Dawn Toolan(5), Monika Kandebo(5), Lihang Yao(5), Mary J. Savage(4), David J. Vocadlo(4), Joseph Duffy(4), Ernest J. McEachern(4), Andrew Singleton(4)